Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan in Metastatic Colorectal Cancer
NCT06820463Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 15
01
Overview
A Phase 2 trial of telisotuzumab adizutecan in metastatic colorectal cancer (mCRC), sponsored by AbbVie Inc.. Started Apr 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06820463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820463.